Prospective randomized comparative study of the effect of pemafibrate add‐on or double statin dose on small dense low‐density lipoprotein‐cholesterol in patients with type 2 diabetes and hypertriglyceridemia on statin therapy

Prospective randomized comparative study of the effect of pemafibrate add‐on or double statin dose on small dense low‐density lipoprotein‐cholesterol in patients with type 2 diabetes and hypertriglyceridemia on statin therapy

Abstract Aims/Introduction Small dense low‐density lipoprotein (sdLDL) is a more potent atherogenic lipoprotein than LDL. As sdLDL‐cholesterol (C) levels are determined by triglyceride and LDL‐C levels, pemafibrate and statins can reduce sdLDL‐C levels. However, it remains unclear whether adding pem...

সম্পূর্ণ বিবরণ

গ্রন্থ-পঞ্জীর বিবরন
প্রধান লেখক:	Tsutomu Hirano, Toshiyuki Hayashi, Hiroe Sugita, Atsuko Tamasawa, Satoshi Goto, Masako Tomoyasu, Takeshi Yamamoto, Makoto Ohara, Michishige Terasaki, Hideki Kushima, Yasuki Ito, Sho‐ichi Yamagishi, Yusaku Mori
বিন্যাস:	প্রবন্ধ
ভাষা:	English
প্রকাশিত:	Wiley 2023-12-01
মালা:	Journal of Diabetes Investigation
বিষয়গুলি:	Pemafibrates Small dense low‐density lipoprotein Type 2 diabetes
অনলাইন ব্যবহার করুন:	https://doi.org/10.1111/jdi.14076

অনুরূপ উপাদানগুলি

Case series showing the safety and changes in lipid profiles of hemodialysis patients with hypertriglyceridemia after pemafibrate administration
অনুযায়ী: Rino Okada, অন্যান্য
প্রকাশিত: (2024-12-01)

Efficacy of Pemafibrate in Comparison to Fenofibrate and Bezafibrate on Triglyceride Levels and Liver, and Renal Functions in Patients With Hypertriglyceridemia and Type 2 Diabetes
অনুযায়ী: Junko Oya, অন্যান্য
প্রকাশিত: (2023-11-01)

Usefulness of pemafibrate for non-alcoholic fatty liver disease with hypertriglyceridemia
অনুযায়ী: Masahiro Kikuchi, অন্যান্য
প্রকাশিত: (2024-09-01)

Favorable Effect of Pemafibrate on Insulin Resistance and β-Cell Function in Subjects with Type 2 Diabetes and Hypertriglyceridemia: A Subanalysis of the PARM-T2D Study
অনুযায়ী: Hiroshi Nomoto, অন্যান্য
প্রকাশিত: (2023-06-01)

Effect and safety of pemafibrate for patients with type 2 diabetes mellitus and hypertriglyceridemia: a retrospective analysis of clinical data
অনুযায়ী: Aki Okamoto, অন্যান্য
প্রকাশিত: (2025-02-01)

Pemafibrate prevents choroidal neovascularization in a mouse model of neovascular age-related macular degeneration
অনুযায়ী: Deokho Lee, অন্যান্য
প্রকাশিত: (2023-01-01)

Preferable effects of pemafibrate on liver function and fibrosis in subjects with type 2 diabetes complicated with liver damage
অনুযায়ী: Hiroshi Nomoto, অন্যান্য
প্রকাশিত: (2023-10-01)

Effect of fenofibrate and selective PPARα modulator (SPPARMα), pemafibrate on KATP channel activity and insulin secretion
অনুযায়ী: Shigeki Kitamura, অন্যান্য
প্রকাশিত: (2023-09-01)

Long-Term pemafibrate treatment exhibits limited impact on body fat mass in patients with hypertriglyceridemia accompanying NAFLD
অনুযায়ী: Takanobu Iwadare, অন্যান্য
প্রকাশিত: (2024-05-01)

Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis
অনুযায়ী: Shizuya Yamashita, অন্যান্য
প্রকাশিত: (2023-05-01)

Effect of pemafibrate on liver enzymes and shear wave velocity in non-alcoholic fatty liver disease patients
অনুযায়ী: Ryosuke Sugimoto, অন্যান্য
প্রকাশিত: (2023-02-01)

Effect of 48‐week pemafibrate on non‐alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan‐aspartate aminotransferase score
অনুযায়ী: Takeshi Hatanaka, অন্যান্য
প্রকাশিত: (2021-10-01)

Pemafibrate Prevents Rupture of Angiotensin II-Induced Abdominal Aortic Aneurysms
অনুযায়ী: Naofumi Amioka, অন্যান্য
প্রকাশিত: (2022-06-01)

Lessons from PROMINENT and prospects for pemafibrate
অনুযায়ী: Jean-Charles Fruchart, অন্যান্য
প্রকাশিত: (2024-07-01)

Effects of Switching from Fenofibrate to Pemafibrate for Asymptomatic Primary Biliary Cholangitis
অনুযায়ী: Kazufumi Dohmen, অন্যান্য
প্রকাশিত: (2021-10-01)

Corrigendum: The effects of pemafibrate and Omega-3 fatty acid ethyl on apoB-48 in dyslipidemic patients treated with statin: A prospective, multicenter, open-label, randomized, parallel group trial in Japan (PROUD48 study)
অনুযায়ী: Yasutaka Takeda, অন্যান্য
প্রকাশিত: (2023-03-01)

The effects of pemafibrate and omega-3 fatty acid ethyl on apoB-48 in dyslipidemic patients treated with statin: A prospective, multicenter, open-label, randomized, parallel group trial in Japan (PROUD48 study)
অনুযায়ী: Yasutaka Takeda, অন্যান্য
প্রকাশিত: (2023-01-01)

Pemafibrate Ameliorates Liver Dysfunction and Fatty Liver in Patients with Non-Alcoholic Fatty Liver Disease with Hypertriglyceridemia: A Retrospective Study with the Outcome after a Mid-Term Follow-Up
অনুযায়ী: Suguru Ikeda, অন্যান্য
প্রকাশিত: (2021-12-01)

Pemafibrate Protects against Fatty Acid-Induced Nephropathy by Maintaining Renal Fatty Acid Metabolism
অনুযায়ী: Daiki Aomura, অন্যান্য
প্রকাশিত: (2021-06-01)

Clinically Relevant Dose of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα), Lowers Serum Triglyceride Levels by Targeting Hepatic PPARα in Mice
অনুযায়ী: Zhe Zhang, অন্যান্য
প্রকাশিত: (2022-07-01)

Pemafibrate Improves Alanine Aminotransferase Levels Independently of Its Lipid-Lowering Effect
অনুযায়ী: Azuma Watanabe, অন্যান্য
প্রকাশিত: (2023-10-01)

Higher Responsiveness for Women, High Transaminase Levels, and Fat Percentage to Pemafibrate Treatment for NAFLD
অনুযায়ী: Takanobu Iwadare, অন্যান্য
প্রকাশিত: (2022-11-01)

Evaluation of the effects of pemafibrate on metabolic dysfunction‐associated steatotic liver disease with hypertriglyceridemia using magnetic resonance elastography combined with fibrosis‐4 index and the magnetic resonance imaging‐aspartate aminotransferase score
অনুযায়ী: Takeshi Ichikawa, অন্যান্য
প্রকাশিত: (2023-12-01)

Effectiveness of Pemafibrate Dose Escalation on Metabolic Dysfunction-Associated Steatotic Liver Disease Refractory to Standard Dose
অনুযায়ী: Satoshi Shinozaki, অন্যান্য
প্রকাশিত: (2025-02-01)

Effects of a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator, Pemafibrate, on Metabolic Parameters: A Retrospective Longitudinal Study
অনুযায়ী: Hidekatsu Yanai, অন্যান্য
প্রকাশিত: (2022-02-01)

Impact of pemafibrate in patients with metabolic dysfunction‐associated steatotic liver disease complicated by dyslipidemia: A single‐arm prospective study
অনুযায়ী: Hiroki Ono, অন্যান্য
প্রকাশিত: (2024-04-01)

Luseogliflozin attenuates neointimal hyperplasia after wire injury in high-fat diet-fed mice via inhibition of perivascular adipose tissue remodeling
অনুযায়ী: Yusaku Mori, অন্যান্য
প্রকাশিত: (2019-10-01)

Effectiveness of One-Year Pemafibrate Therapy on Non-Alcoholic Fatty Liver Disease Refractory to Long-Term Sodium Glucose Cotransporter-2 Inhibitor Therapy: A Pilot Study
অনুযায়ী: Satoshi Shinozaki, অন্যান্য
প্রকাশিত: (2023-06-01)

The role of endothelial nitric oxide in the anti-restenotic effects of liraglutide in a mouse model of restenosis
অনুযায়ী: Hideki Kushima, অন্যান্য
প্রকাশিত: (2017-10-01)

Effect of statin add-on therapy on cardiovascular mortality
অনুযায়ী: John R. Nelson, অন্যান্য
প্রকাশিত: (2024-03-01)

Emphysematous cystitis in an elderly Japanese patient with type 2 diabetes mellitus
অনুযায়ী: Hironori Yashima, অন্যান্য
প্রকাশিত: (2019-03-01)

Persistent hypertriglyceridemia in statin-treated patients with type 2 diabetes mellitus
অনুযায়ী: Feher M, অন্যান্য
প্রকাশিত: (2013-01-01)

Comparison of positive rates between glutamic acid decarboxylase antibodies and ElisaRSR™ 3 Screen ICA™ in recently obtained sera from patients who had been previously diagnosed with slowly progressive type 1 diabetes
অনুযায়ী: Nobuaki Takehana, অন্যান্য
প্রকাশিত: (2023-07-01)

Current Clinical Trial Status and Future Prospects of PPAR-Targeted Drugs for Treating Nonalcoholic Fatty Liver Disease
অনুযায়ী: Shotaro Kamata, অন্যান্য
প্রকাশিত: (2023-08-01)

Glucose-Dependent Insulinotropic Polypeptide Suppresses Foam Cell Formation of Macrophages through Inhibition of the Cyclin-Dependent Kinase 5-CD36 Pathway
অনুযায়ী: Michishige Terasaki, অন্যান্য
প্রকাশিত: (2021-07-01)

Combination Therapy with a Sodium-Glucose Cotransporter 2 Inhibitor and a Dipeptidyl Peptidase-4 Inhibitor Additively Suppresses Macrophage Foam Cell Formation and Atherosclerosis in Diabetic Mice
অনুযায়ী: Michishige Terasaki, অন্যান্য
প্রকাশিত: (2017-01-01)

Comparing efficacy of fibrates and statins in isolated and combined hypertriglyceridemia and various types of oxidative metabolism
অনুযায়ী: G. S. Mal’
প্রকাশিত: (2005-06-01)

Amelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice.
অনুযায়ী: Michishige Terasaki, অন্যান্য
প্রকাশিত: (2015-01-01)

Analysis of serum levels and DNA methylation of fibroblast growth factor 21 using peripheral blood-derived genomes in patients with obesity
অনুযায়ী: Hiroyuki Shinozaki, অন্যান্য
প্রকাশিত: (2024-09-01)

No change in small low‐density lipoprotein cholesterol levels with pemafibrate might explain the negative results of the PROMINENT trial
অনুযায়ী: Tsutomu Hirano
প্রকাশিত: (2023-04-01)